RYTM - Rhythm Pharmaceuticals, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
Boston,
United States
Type: Equity
RYTM price evolution
RYTM
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $60.41 | $64.92 | $116.01 | $109.99 |
| Short term investments | $215.76 | $234.67 | $137.92 | $184.92 |
| Net receivables | $14.87 | $14.54 | $13.83 | $8.12 |
| Inventory | $8.62 | $7.76 | $6.18 | $5.49 |
| Total current assets | $308.27 | $329.2 | $283.88 | $317.84 |
| Long term investments | ||||
| Property, plant & equipment | $2.12 | $2.43 | $2.76 | $3.09 |
| Goodwill & intangible assets | $7.03 | $7.24 | $7.46 | $7.67 |
| Total noncurrent assets | $24.48 | $25 | $26.07 | $27.84 |
| Total investments | $215.76 | $234.67 | $137.92 | $184.92 |
| Total assets | $332.75 | $354.2 | $309.94 | $345.68 |
| Current liabilities | ||||
| Accounts payable | $4.88 | $3.84 | $8.38 | $13.35 |
| Deferred revenue | $1.29 | $1.29 | $1.29 | $1.43 |
| Short long term debt | $0.77 | $0.75 | $0.73 | $0.7 |
| Total current liabilities | $55.2 | $50.14 | $46.1 | $46.03 |
| Long term debt | $0.49 | $0.69 | $0.89 | $1.08 |
| Total noncurrent liabilities | $107.78 | $106.58 | $81.56 | $79.89 |
| Total debt | $1.26 | $1.44 | $1.61 | $1.78 |
| Total liabilities | $162.99 | $156.72 | $127.66 | $125.92 |
| Shareholders' equity | ||||
| Retained earnings | -$894.74 | -$853.1 | -$808.94 | -$762.24 |
| Other shareholder equity | $0.13 | -$0.11 | -$0.01 | -$0.01 |
| Total shareholder equity | $169.76 | $197.47 | $182.28 | $219.76 |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $60.41 | $128 | $59.58 | $101.26 |
| Short term investments | $215.76 | $205.61 | $235.61 | $71.94 |
| Net receivables | $14.87 | $6.22 | $1.02 | |
| Inventory | $8.62 | $2.92 | ||
| Total current assets | $308.27 | $354.24 | $308.39 | $181.67 |
| Long term investments | ||||
| Property, plant & equipment | $2.12 | $3.38 | $4.33 | $5 |
| Goodwill & intangible assets | $7.03 | $7.88 | $4.66 | |
| Total noncurrent assets | $24.48 | $28.25 | $21.14 | $5.41 |
| Total investments | $215.76 | $205.61 | $235.61 | $71.94 |
| Total assets | $332.75 | $382.48 | $329.52 | $187.07 |
| Current liabilities | ||||
| Accounts payable | $4.88 | $4.8 | $5.74 | $4.9 |
| Deferred revenue | $1.29 | $1.43 | ||
| Short long term debt | $0.77 | $0.68 | $0.61 | $0.54 |
| Total current liabilities | $55.2 | $39.81 | $43.43 | $17.99 |
| Long term debt | $0.49 | $75.81 | $1.95 | $2.55 |
| Total noncurrent liabilities | $107.78 | $78.41 | $1.95 | $2.55 |
| Total debt | $1.26 | $1.94 | $2.55 | $3.09 |
| Total liabilities | $162.99 | $118.22 | $45.37 | $20.55 |
| Shareholders' equity | ||||
| Retained earnings | -$894.74 | -$710.06 | -$528.94 | -$459.33 |
| Other shareholder equity | $0.13 | -$0.09 | -$0 | $0.05 |
| Total shareholder equity | $169.76 | $264.26 | $284.15 | $166.53 |
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $24.23 | $22.5 | $19.22 | $11.47 |
| Cost of revenue | $3.23 | $2.41 | $2.24 | $1.42 |
| Gross Profit | $21 | $20.09 | $16.98 | $10.05 |
| Operating activities | ||||
| Research & development | $29.89 | $33.57 | $33.54 | $37.95 |
| Selling, general & administrative | $32.37 | $30.48 | $30.05 | $24.63 |
| Total operating expenses | $62.27 | $64.05 | $63.59 | $62.58 |
| Operating income | -$41.27 | -$43.95 | -$46.6 | -$52.53 |
| Income from continuing operations | ||||
| EBIT | -$36.89 | -$40.65 | -$43.4 | -$49.12 |
| Income tax expense | $0.2 | $0.37 | ||
| Interest expense | $4.55 | $3.15 | $3.3 | $3.06 |
| Net income | ||||
| Net income | -$41.63 | -$44.16 | -$46.7 | -$52.18 |
| Income (for common shares) | -$41.63 | -$44.16 | -$46.7 | -$52.18 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $77.43 | $23.64 | $3.15 | |
| Cost of revenue | $9.3 | $2.13 | $0.6 | |
| Gross Profit | $68.13 | $21.5 | $2.56 | |
| Operating activities | ||||
| Research & development | $134.95 | $108.63 | $104.13 | $90.45 |
| Selling, general & administrative | $117.53 | $92.03 | $68.49 | $46.13 |
| Total operating expenses | $252.48 | $200.66 | $172.61 | $136.57 |
| Operating income | -$184.36 | -$179.16 | -$170.06 | -$136.57 |
| Income from continuing operations | ||||
| EBIT | -$170.22 | -$175.92 | -$69.61 | -$134 |
| Income tax expense | $0.56 | |||
| Interest expense | $13.89 | $5.2 | ||
| Net income | ||||
| Net income | -$184.68 | -$181.12 | -$69.61 | -$134 |
| Income (for common shares) | -$184.68 | -$181.12 | -$69.61 | -$134 |
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Net income | -$41.63 | -$44.16 | -$46.7 | -$52.18 |
| Operating activities | ||||
| Depreciation | $0.42 | $0.44 | $0.44 | $0.46 |
| Business acquisitions & disposals | -$0.27 | -$0.88 | -$4.52 | |
| Stock-based compensation | $8.67 | $8.61 | $8.89 | $6.38 |
| Total cash flows from operations | -$29.38 | -$29.25 | -$41.09 | -$36.43 |
| Investing activities | ||||
| Capital expenditures | $0 | -$0 | -$0.05 | |
| Investments | $22.64 | -$94.69 | $49.07 | $23.03 |
| Total cash flows from investing | $22.64 | -$94.96 | $48.19 | $18.46 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $5 | $50.84 | $0.34 | $1.22 |
| Net borrowings | $24.37 | |||
| Total cash flows from financing | $2.42 | $73.04 | -$0.96 | -$0.13 |
| Effect of exchange rate | -$0.19 | $0.08 | -$0.11 | $0.09 |
| Change in cash and equivalents | -$4.51 | -$51.09 | $6.02 | -$18.02 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$184.68 | -$181.12 | -$69.61 | -$134 |
| Operating activities | ||||
| Depreciation | $1.76 | $1.67 | $1.16 | $0.69 |
| Business acquisitions & disposals | -$5.67 | |||
| Stock-based compensation | $32.55 | $19.83 | $20.8 | $17.45 |
| Total cash flows from operations | -$136.16 | -$173.43 | -$146 | -$121.98 |
| Investing activities | ||||
| Capital expenditures | -$0.05 | -$0.28 | $99.57 | -$0.21 |
| Investments | $0.05 | $32.31 | -$163.72 | $158.75 |
| Total cash flows from investing | -$5.67 | $28.03 | -$62.16 | $158.53 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $57.4 | $141.49 | $166.48 | $2.01 |
| Net borrowings | $24.37 | $72.34 | ||
| Total cash flows from financing | $74.37 | $213.83 | $166.48 | $2.01 |
| Effect of exchange rate | -$0.14 | |||
| Change in cash and equivalents | -$67.6 | $68.43 | -$41.68 | $38.56 |
News
Fundamentals
| Market cap | $2.27B |
|---|---|
| Enterprise value | $2.21B |
| Shares outstanding | 59.43M |
| Revenue | $77.43M |
|---|---|
| EBITDA | -$168.29M |
| EBIT | -$170.05M |
| Net Income | -$184.68M |
| Revenue Q/Q | 175.70% |
| Revenue Y/Y | 227.56% |
| P/E ratio | -12.28 |
|---|---|
| EV/Sales | 28.52 |
| EV/EBITDA | -13.12 |
| EV/EBIT | -12.98 |
| P/S ratio | 29.28 |
| P/B ratio | 13.37 |
| Book/Share | 2.85 |
| Cash/Share | 1.02 |
| EPS | -$3.11 |
|---|---|
| ROA | -55.02% |
| ROE | -96.03% |
| Debt/Equity | 0.96 |
|---|---|
| Net debt/EBITDA | -0.61 |
| Current ratio | 5.58 |
| Quick ratio | 5.43 |